The Long and Winding Road to Useful Predictive Factors for Anti-EGFR Therapy in Metastatic Colorectal Carcinoma: The KRAS/BRAF Pathway

Publisher： Karger

E-ISSN： 1423-0232|77|1|57-68

ISSN： 0030-2414

Source： Oncology, Vol.77, Iss.1, 2010-02, pp. : 57-68

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Benefit of High-Sensitivity KRAS Mutation Testing in Metastatic Colorectal Cancer Treated with Anti-EGFR Antibody Therapy

By  

Oncology, Vol. 82, Iss. 5, 2012-04 ,pp. : 298-304

Karger

Access to resources Recommend Favorite

Toward an individualizing therapy for colorectal cancer: the example of the anti-EGFR monoclonal antibodies

By Lièèvre Astrid   Laurent-Puig Pierre  

Personalized Medicine, Vol. 6, Iss. 2, 2009-03 ,pp. : 145-157

Future Medicine

Access to resources Recommend Favorite

Elucidating the prognostic significance of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese patients with metastatic colorectal cancer

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 11, Iss. 2, 2015-06 ,pp. : 160-169

John Wiley & Sons Inc

Access to resources Recommend Favorite

Hyperplastic polyps of the colon and rectum – reclassification, BRAF and KRAS status in index polyps and subsequent colorectal carcinoma

By  

APMIS (ELECTRONIC), Vol. 123, Iss. 4, 2015-04 ,pp. : 298-304

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Role of KRAS Mutations in Predicting the Efficacy of Cetuximab-Plus-Irinotecan Therapy in Irinotecan-Refractory Korean Metastatic Colorectal Cancer Patients

By  

Oncology, Vol. 77, Iss. 3-4, 2009-09 ,pp. : 224-230

Karger

Access to resources Recommend Favorite